Related Experiment Videos
Apoptosis in sepsis: a new target for therapeutic exploration
C Oberholzer1, A Oberholzer, M Clare-Salzler
1Departments of Surgery, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
Abstract:
The treatment of sepsis and septic shock remains a clinical conundrum, and recent prospective trials with biological response modifiers aimed at the inflammatory response have shown only modest clinical benefit. Recently, interest has shifted toward therapies aimed at reversing the accompanying periods of immune suppression. Studies in experimental animals and critically ill patients have demonstrated that increased apoptosis of lymphoid organs and some parenchymal tissues contributes to this immune suppression, anergy, and organ system dysfunction. During sepsis syndromes, lymphocyte apoptosis can be triggered by the absence of IL-2 or by the release of glucocorticoids, granzymes, or the so-called 'death' cytokines: tumor necrosis factor alpha or Fas ligand. Apoptosis proceeds via auto-activation of cytosolic and/or mitochondrial caspases, which can be influenced by the pro- and anti-apoptotic members of the Bcl-2 family. In experimental animals, not only can treatment with inhibitors of apoptosis prevent lymphoid cell apoptosis; it may also improve outcome. Although clinical trials with anti-apoptotic agents remain distant due in large part to technical difficulties associated with their administration and tissue targeting, inhibition of lymphocyte apoptosis represents an attractive therapeutic target for the septic patient.
Insights
Inhibiting lymphocyte apoptosis, a key factor in sepsis-induced immune suppression, shows promise for improving patient outcomes. Further research into anti-apoptotic therapies could offer new treatments for sepsis and septic shock.
Area of Science:
- Immunology
- Critical Care Medicine
- Molecular Biology
Background:
- Sepsis and septic shock treatment remains challenging, with limited success from anti-inflammatory therapies.
- Immune suppression, characterized by increased apoptosis (programmed cell death) in lymphoid organs and tissues, contributes to sepsis-related dysfunction.
- Lymphocyte apoptosis during sepsis is triggered by factors like IL-2 absence, glucocorticoids, granzymes, and death cytokines (TNF-alpha, Fas ligand).
Purpose of the Study:
- To explore the role of apoptosis in sepsis-induced immune suppression.
- To investigate the potential of inhibiting lymphocyte apoptosis as a therapeutic strategy for sepsis.
Main Methods:
- Review of experimental animal studies and critically ill patient data.
- Analysis of molecular mechanisms of apoptosis, including caspases and Bcl-2 family proteins.
- Evaluation of the impact of apoptosis inhibitors in experimental models.
Main Results:
- Increased apoptosis of lymphoid and parenchymal tissues is a significant contributor to sepsis-induced immune suppression and organ dysfunction.
- Inhibition of apoptosis in experimental animals has demonstrated the potential to prevent lymphocyte apoptosis and improve outcomes.
- Apoptosis is mediated by caspases and influenced by the Bcl-2 family of proteins.
Conclusions:
- Inhibiting lymphocyte apoptosis presents a promising therapeutic target for sepsis patients.
- While clinical application faces challenges, targeting apoptosis offers a novel approach beyond traditional anti-inflammatory strategies.
- Further development of anti-apoptotic agents is warranted for sepsis treatment.